公开(公告)号：US12116397B2

公开(公告)日：2024-10-15

申请号：US16498186

申请日：2018-04-03

Applicant: Swedish Orphan Biovitrum AB (publ)

Inventor： Joachim Feldwisch ,  Malin Lindborg ,  Joakim Nilsson ,  Erik Nordling ,  Robert Svensson

IPC: A61K38/16 ,  C07K14/715 ,  C07K14/79 ,  A61K38/00

CPC classification number: C07K14/7155 ,  C07K14/79 ,  A61K38/00 ,  C07K2318/20 ,  C07K2319/21 ,  C07K2319/31

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif (BM) EX2X3X4X5X6X7EIX10X11LPNLX16RX18QYX21AFIX25X26LX28D. The present disclosure also relates to the use of such an IL-1R-I binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

公开(公告)号：US20240335537A1

公开(公告)日：2024-10-10

申请号：US18681931

申请日：2022-08-12

Applicant: Baylor College of Medicine

Inventor： Pradip Bajgain ,  Juan Fernando Vera Valdes ,  Ann Marie Leen ,  Mohsen Basiri

IPC: A61K39/00 ,  A61K38/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715

CPC classification number: A61K39/4635 ,  A61K39/4611 ,  A61K39/4613 ,  A61P35/00 ,  C07K14/5418 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/70578 ,  C07K14/71 ,  C07K14/7155 ,  A61K38/00

Abstract: Disclosed herein are methods and compositions for modulating immune responses by using decoy molecules to bind to soluble or other ligands. In specific embodiments, the decoy molecules comprise a domain that binds to a target immunosuppressive ligand and another domain that releases immunostimulatory signals when activated. In specific embodiments, the decoy molecules are soluble and are secreted by transgenic T cells at a tumor site, such as upon antigen engagement, and they protect the transgenic cells themselves and also bystander (e.g., non-modified) endogenous immune cells.

公开(公告)号：US20240317836A1

公开(公告)日：2024-09-26

申请号：US18679187

申请日：2024-05-30

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong

IPC: C07K14/715 ,  A61K38/17 ,  A61K38/19 ,  A61K38/20 ,  A61K45/06 ,  C07K14/52 ,  C07K14/54 ,  C07K14/71

CPC classification number: C07K14/7155 ,  A61K38/179 ,  A61K38/1793 ,  A61K38/195 ,  A61K38/2086 ,  A61K45/06 ,  C07K14/521 ,  C07K14/5443 ,  C07K14/71 ,  C07K2319/30 ,  C07K2319/31

Abstract: Compositions, methods, and uses of recombinant immunoglobulin proteins, recombinant immunoglobulin protein complexes, carrier protein complexes, and a pharmaceutical composition including one or more of those to increase immune therapy effectiveness are presented. Preferred protein and protein complex comprise one or more functional moieties that includes a binding motif to a tumor-associated antigen, a T-cell activating molecule, and a chemokine. In some embodiments, the pharmaceutical composition includes two or more protein complexes, which are functionally distinct from each other. In other embodiments, the pharmaceutical composition includes a genetically-engineered microorganism including a first tumor-associated antigen and a T-cell activating molecule, a recombinant immunoglobulin protein complex, and a chemokine.

公开(公告)号：US20240299543A1

公开(公告)日：2024-09-12

申请号：US18275258

申请日：2022-02-02

Applicant: Carisma Therapeutics Inc.

Inventor： Michael Klichinsky ,  David Christopher Sloas ,  Nicholas Roy Anderson

IPC: A61K39/00 ,  C07K14/54 ,  C07K14/565 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0786 ,  C12N15/86

CPC classification number: A61K39/4614 ,  A61K39/4631 ,  C07K14/5428 ,  C07K14/565 ,  C07K14/7051 ,  C07K14/7155 ,  C07K14/7156 ,  C12N5/0645 ,  C12N15/86 ,  C07K2319/02 ,  C07K2319/50 ,  C12N2501/00 ,  C12N2740/15041 ,  C12N2750/14141

Abstract: The present disclosure pertains to modified immune cells comprising fusion proteins and methods of using and making immune cells comprising fusion proteins. The present disclosure also pertains to modified immune cells comprising exogenous cytokines and chimeric antigen receptors and methods of using and making said immune cells.

公开(公告)号：US20240238420A1

公开(公告)日：2024-07-18

申请号：US18415188

申请日：2024-01-17

Applicant: Wuhan University

Inventor： Ying ZHANG ,  Guohua CAO ,  Ruijin JI

IPC: A61K39/00 ,  C07K14/715 ,  C12N9/22 ,  C12N15/11

CPC classification number: A61K39/464419 ,  A61K39/461 ,  A61K39/4631 ,  A61K39/4633 ,  C07K14/7155 ,  C12N9/22 ,  C12N15/11 ,  C12N2310/20

Abstract: The present disclosure describes compositions and methods for treating cancers such as acute myeloid leukemia (AML), in particular relapsed and refractory AML. The method entails administering to the patient an antibody or a chimeric antigen receptor (CAR)-expressing immune cell targeting a molecule such as CD33, CD123, CD117 or CLL-1 following, or concurrently with, transplanting to the patient an engineered stem cell expressing the same molecule but with a mutation disrupting the epitope to the antibody or CAR. Due to the mutation, the engineered stem cell, unlike endogenous hematopoietic cells, is not targeted by the therapy and thus can supply the patient with functional hematopoietic cells and antigens.

公开(公告)号：US12037596B2

公开(公告)日：2024-07-16

申请号：US17196408

申请日：2021-03-09

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jeffrey D. Lee ,  Alexander O. Mujica ,  Wojtek Auerbach ,  Ka-Man Venus Lai ,  David M. Valenzuela ,  George D. Yancopoulos

IPC: A01K67/0278 ,  A01K67/0276 ,  A61D19/04 ,  C07K14/715 ,  C07K14/775 ,  C12N15/85 ,  C12N15/90

CPC classification number: C12N15/8509 ,  A01K67/0276 ,  A01K67/0278 ,  A61D19/04 ,  C07K14/7155 ,  C07K14/775 ,  C12N15/907 ,  A01K2217/07 ,  A01K2227/105 ,  A01K2267/0362 ,  A01K2267/0381 ,  C12N2015/8527 ,  C12N2800/30 ,  C12N2810/00

Abstract: Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (LTVEC) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. Compositions and methods are provided which comprise a genetically modified rat or rat cell comprising a targeted genetic modification in the rat interleukin-2 receptor gamma locus, the rat ApoE locus, the rat Rag2 locus, the rat Rag1 locus and/or the rat Rag2/Rag1 locus. The various methods and compositions provided herein allows for these modified loci to be transmitted through the germline.

公开(公告)号：US20240218047A1

公开(公告)日：2024-07-04

申请号：US17051160

申请日：2019-05-03

Applicant: IMMUNE TARGETING INC.

Inventor： Yang-Xin Fu ,  Hua Peng ,  Jingya Guo

IPC: C07K14/715 ,  A61K38/00 ,  A61P35/00 ,  C07K14/54 ,  C12N15/62

CPC classification number: C07K14/7155 ,  A61P35/00 ,  C07K14/5443 ,  C12N15/62 ,  A61K38/00 ,  C07K2319/30

Abstract: The invention provides novel fusion proteins of Interleukin 15 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).

公开(公告)号：US20240209096A1

公开(公告)日：2024-06-27

申请号：US18396077

申请日：2023-12-26

Applicant: Invetx, Inc.

Inventor： William BRONDYK

IPC: C07K16/28 ,  C07K14/505 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K14/72 ,  C07K16/18 ,  C07K16/24 ,  C07K16/26

CPC classification number: C07K16/283 ,  C07K14/505 ,  C07K14/70521 ,  C07K14/70528 ,  C07K14/71 ,  C07K14/7155 ,  C07K14/72 ,  C07K16/18 ,  C07K16/244 ,  C07K16/245 ,  C07K16/246 ,  C07K16/247 ,  C07K16/26 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/2875 ,  C07K16/2887 ,  C07K16/2893 ,  C07K16/2896 ,  A61K2039/505 ,  C07K2317/20 ,  C07K2319/30

Abstract: Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a canine and methods of their use. The compositions involve variant canine IgG Fc regions.

公开(公告)号：US11992516B2

公开(公告)日：2024-05-28

申请号：US18045572

申请日：2022-10-11

Applicant: Altor Bioscience, LLC

Inventor： Bai Liu ,  Peter Rhode ,  Wenxin Xu ,  Hing C. Wong

IPC: A61K39/395 ,  A61K38/17 ,  A61K38/20 ,  A61K47/64 ,  A61P35/00 ,  A61K39/04 ,  C07K14/35 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K38/2086 ,  A61K38/1793 ,  A61K39/39558 ,  A61K47/6425 ,  A61P35/00 ,  A61K39/04 ,  C07K14/35 ,  C07K14/5443 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/732 ,  C07K2319/30 ,  C07K2319/32 ,  A61K38/2086 ,  A61K2300/00

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

公开(公告)号：US11987804B2

公开(公告)日：2024-05-21

申请号：US17049782

申请日：2019-04-25

Applicant: Seattle Children's Hospital

Inventor： Andrew M. Scharenberg ,  David J. Rawlings ,  Karen Sommer ,  Samuel West ,  Yuchi Chiang Honaker ,  Ryo Takeuchi

IPC: C12N15/90 ,  C07K14/715 ,  C12N15/113 ,  C12N15/86

CPC classification number: C12N15/90 ,  C07K14/7155 ,  C12N15/113 ,  C12N15/86 ,  C07K2317/53 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2740/16043 ,  C12N2750/14143

Abstract: The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.